A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
Latest Information Update: 04 Jun 2026
At a glance
- Drugs Taniraleucel (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms CYNKCOVID
- Sponsors Celularity
Most Recent Events
- 01 Jun 2026 Actual primary completion date changed from 30 Dec 2021 to 30 Aug 2021.
- 01 Jun 2026 According to ClinicalTrials.gov: US National Institutes of Health, study was designed to include a Phase 1 dose-escalation portion followed by a randomized Phase 2 portion; however, due to early termination, only Phase 1 participants were enrolled and treated.
- 01 Jun 2026 Status changed from active, no longer recruiting to discontinued.